chevron_leftBack
As of 24 April 2025, Genmab A/S has a market cap of $12.69B USD, ranking #1382 globally and #11 in Denmark. It ranks #118 in the Healthcare sector, and #15 in the Biotechnology industry.
Key Stats
Market Cap
$12.69BUSD
83.24B DKK
Enterprise Value
$9.59BUSD
63.16B DKK
Revenue (TTM)
$3.28BUSD
21.53B DKK
EBITDA (TTM)
$1.12BUSD
7.39B DKK
Net Income (TTM)
$1.2BUSD
7.84B DKK
EBITDA Margin
34%
Profit Margin
36%
PE Ratio
11.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jan G.J. de Winkel
open_in_new
Employees
2,682
Founded
1998
Website
genmab.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.2% | 2.9% | -2.5% | -12% | -14% | -34% |
Upcoming Earnings
Earnings Date
Thu, May 8
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GMAB
Genmab AS
ISIN: DK0010272202
Shares Out.:
Shares Outstanding:
61.473M1
Shares Float:
58.484M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.33K DKK | |
|
0MGB
Genmab AS
ISIN: DK0010272202
|
1.29K DKK | |
|
NASDAQ
MIC: XNAS
|
GMAB
Genmab AS ADR
ISIN: US3723032062
Shares Out.:
Shares Outstanding:
614.734M1
Shares Float:
614.727M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
20.13 USD |
|
GMAB
(GMAB/N)
Genmab AS
ISIN: DK0010272202
|
3.92K MXN | |
|
GNMSF
Genmab AS
ISIN: DK0010272202
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
200.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
